Endocrine evaluation of patients with critical illness

Endocrinology and Metabolism Clinics of North America

Volumn 32, Issue 2, 2003, Pages 385-410

  Van den Berghe, Greet ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOHYPOPHYSIS HORMONE; GONADORELIN; GONADOTROPIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; INSULIN; LIOTHYRONINE; PROTIRELIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADENOHYPOPHYSIS; CRITICAL ILLNESS; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; GLUCOSE BLOOD LEVEL; GONADOTROPIN RELEASE; GROWTH HORMONE RELEASE; HORMONE ACTION; HUMAN; HYPOPHYSIS FUNCTION; MORBIDITY; MORTALITY; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; REVIEW; SURVIVAL RATE; THYROTROPIN RELEASE; WASTING SYNDROME;

EID: 0038657706     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(03)00005-7     Document Type: Review

References (116)

1. Streat SJ, Beddoe AH, Hill GL. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. J Trauma 1987;27:262-6.
2. Carroll P. Protein metabolism and the use of growth hormone and insulin-like growth factor-I in the critically ill patient. Growth Horm IGF Res 1999;9:400-13.
3. Van den Berghe G, Baxter RC, Weekers F, et al. A paradoxical gender dissociation within the growth hormone, insulin-like growth factor I axis during protracted critical illness. J Clin Endocrinol Metab 2000;85:183-92.
4. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29.
5. Van den Berghe G, de Zegher F, Bouillon R. Acute and prolonged critical illness as different neuroendocrine paradigms. J Clin Endocrinol Metab 1998;83:1827-34.
6. Van den Berghe G, Wouters P, Weekers F, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999;84:1311-23.
7. th edition. Philadelphia: W.B. Saunders; 1998. p. 249-340.
8. Bowers CY, Momany FA, Reynolds GA, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984;114:1537-45.
9. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974-7.
10. Masayasu Kojima, Hiroshi Hosoda, Yukari Date, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60.
11. Gevers EF, Wit JM, Robinson IC. Growth, growth hormone (GH) binding protein, and GH receptors are differentially regulated by peak and trough components of GH secretory pattern in the rat. Endocrinology 1996;137:1013-8.
12. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-97.
13. Hindmarsh PC, Dennison E, Pincus SM, et al. A sexually dimorphic pattern of growth hormone secretion in the elderly illness. J Clin Endocrinol Metab 1999;84:2679-85.
14. Ross R, Miell J, Freeman E, Jones J, et al. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-1. Clin Endocrinol 1991;35:47-54.
15. Voerman HJ, Strack van Schijndel RJM, de Boer H, et al. Growth hormone: secretion and administration in catabolic adult patients, with emphasis on the critically ill patient. Neth J Med 1992;41:229-44.
16. Hartman ML, Veldhuis JD, Johnson ML, et al. Augmented growth hormone secretory burst frequency and amplitude mediate enhanced GH secretion during a two day fast in normal men. J Clin Endocrinol Metab 1992;74:757-65.
17. Hermansson M, Wickelgren RB, Hammerqvist F, et al. Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. J Clin Endocrinol Metab 1997;82:421-8.
18. Baxter RC, Hawker FH, To C, et al. Thirty day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients. Growth Horm IGF Res 1998;8:455-63.
19. Rodriguez-Arnao J, Yarwood Y, Ferguson C, et al. Reduction in circulating IGF-I and hepatic IGF-I mRNA levels after ceacal ligation and puncture are associated with differential regulation of hepatic IGF-binding protein-1, -2 and -3 mRNA levels. J Endocrinol 1996;151:287-92.
20. Bentham J, Rodriguez-Arnao J, Ross RJ. Acquired growth hormone resistance in patients with hypecatabolism. Horm Res 1993;40:87-91.
21. Timmins AC, Cotterill AM, Cwyfan Hughes SC, et al. Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein-3 protease. Crit Care Med 1996;24:1460-6.
22. Gibson FA, Hinds CJ. Growth Hormone and insulin-like growth factors in critical illness. Intens Care Med 1997;23:369-78.
23. Van den Berghe G, Baxter RC, Weekers F, et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects than treatment with GHRP-2 alone. Clin Endocrinol 2002;56:655-69.
24. Van den Berghe G, de Zegher F, Veldhuis JD, et al. The somatotropic axis in critical illness: effect of continuous GHRH and GHRP-2 infusion. J Clin Endocrinol Metab 1997;82:590-9.
25. Van den Berghe G, de Zegher F, Baxter RC, et al. Neuroendocrinology of prolonged critical illness: effect of continuous thyrotropin-releasing hormone infusion and its combination with growth hormone-secretagogues. J Clin Endocrinol Metab 1998;83:309-19.
26. Van den Berghe G, de Zegher F, Lauwers P, et al. Growth hormone secretion in critical illness: effect of dopamine. J Clin Endocrinol Metab 1994;79:1141-6.
27. Van den Berghe G, de Zegher F. Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996;24:1580-90.
28. Micic D, Popovic V, Doknic M, et al. Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6. J Clin Endocrinol Metab 1998;83:2569-72.
29. Van den Berghe G, de Zegher F, Bowers CY, et al. Pituitary responsiveness to growth hormone (GH) releasing hormone, GH-releasing peptide-2 and thyrotropin releasing hormone in critical illness. Clin Endocrinol 1996;45:341-51.
30. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-92.
31. Van den Berghe G. Whither growth hormone in the catabolic state of critical illness? Growth Horm IGF Res 1999;9:397-9.
32. Christiansen JS, Bengtsson BA, Thorner MO, et al. Critical Evaluation of the safety of recombinant human growth hormone administration: statement from the growth hormone research society. J Clin Endocrinol Metab 2001;86:1868-70.
33. Michalaki M, Vagenakis A, Makri M, et al. Dissociation of the early decline in serum T3 concentration and serum IL-6 rise and TNF alfa in non-thyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab 2001;86:4198-205.
34. Chopra IJ, Huang TS, Beredo A, et al. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3′-triiodothyronine in sera of patients with non-thyroidal illness. J Clin Endocrinol Metab 1985;60:666-72.
35. Bartalena L, Martino E, Brandi LS, et al. Lack of nocturnal serum thyrotropin surge after surgery. J Clin Endocrinol Metab 1990;70:293-6.
36. Romijn JA, Wiersinga WM. Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab 1990;70:35-42.
37. Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med 1995;23:78-83.
38. Schlienger JL, Sapin R, Capgras T, et al. Evaluation of thyroid function after myocardial infarction. Ann Endocrinol (Paris) 1991;52:283-8.
39. van der Poll T, van Zee K, Endert E, et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentration in man. J Clin Endocrinol Metab 1995;80:1341-6.
40. Lim CF, Doctor R, Visser TJ, et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of non-uremic critically ill patients: effects of bilirubin and non-esterified fatty acids. J Clin Endocrinol Metab 1993;76:1165-72.
41. Gardner DF, Kaplan MM, Stanley CA, et al. Effect of triiodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 1979;300: 579-584.
42. De Groot LJ. Dangerous dogmas in medicine: the non-thyroidal illness syndrome. J Clin Endocrinol Metab 1999;84:151-64.
43. Kemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary bypass surgery. N Engl J Med 1995;333:1522-7.
44. Mullis-Jansson SL, Argenziano M, Corwin S, et al. A randomized double blind study on the effect of triiodthyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiov Sur 1999;117:1128-34.
45. Van den Berghe G, de Zegher F, Veldhuis JD, et al. Thyrotropin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone secretagogues. Clin Endocrinol 1997;47:599-612.
46. Fliers E, Guldenaar SEF, Wiersinga WM, et al. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with non-thyroidal illness. J Clin Endocrinol Metab 1997;82:4032-6.
47. Bacci V, Schussler GC, Kaplan TC. The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab 1982;54:1229-35.
48. Damas P, Reuter A, Gysen P, et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975-8.
49. Faglia G, Ferrari C, Beck-Peccoz P, et al. Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal humans. Horm Metab Res 1973;5:289-91.
50. Van den Berghe G, de Zegher F, Vlasselaers D, et al. Thyrotropin Releasing Hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin and growth hormone concentrations. Crit Care Med 1996; 24:590-5.
51. Van den Berghe G, Wouters P, Bowers CY, et al. Growth hormone releasing peptide-2 infusion synchronizes growth hormone, thyrotropin and prolactin secretion in prolonged critical illness. Eur J Endocrinol 1999;140:17-22.
52. Arem R, Wiener GJ, Kaplan SG, et al. Reduced tissue thyroid hormone levels in fatal illness. Metabolism 1993;42:1102-8.
53. Vaughan GM, Mason AD, McManus WF, et al. Alterations of mental status and thyroid hormones after thermal injury. J Clin Endocrinol Metab 1985;60:1221-5.
54. Brent GA, Hershman JM. Thyroxine therapy in patients with severe non-thyroidal illnesses and low serum thyroxine concentrations. J Clin Endocrinol Metab 1986;63: 1-7.
55. Becker RA, Vaughan GM, Ziegler MG, et al. Hypermetabolic low triiodothyronine syndrome in burn injury. Crit Care Med 1982;10:870-5.
56. Bettendorf M, Schmidt KG, Grulich-Henn J, et al. Triiodothyronine treatment in children after cardiac surgery: a double-blind, randomized, placebo-controlled study. Lancet 2000;356:529-34.
57. Nicoloff JT. Thyroid storm and myxedema coma. Med Clin North Am 1985;69:1005-17.
58. Ringel MD. Management of hypothyroidism and hyperthyroidism in the intensive care unit. Crit Care Clin 2001;17:59-74.
59. Kaptein EM, Quion-Verde H, Swinney RS, Egodage PM, Massry SG. Acute hemodynamic effects of levothyroxine loading in critically ill hypothyroid patients. Arch Intern Med 1986;146:662-6.
60. Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 1995; 96:2828-38.
61. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ. Effects of thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999;340:424-9.
62. Wiersinga WM. Thyroid hormone replacement therapy. Horm Res 2001;56:74-81.
63. Russell DH. New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation. Trends Pharmacol Sci 1989;10:40-4.
64. Bernton EW, Meltzer MS, Holaday JW. Suppression of macrophage activation and Tlymphocyte function in hypoprolactinemic mice. Science 1988;239:401-4.
65. Russell DH, Larson DF, Cardon SB, et al. Cyclosporin inhibits prolactin induction of ornithinedecarboxilase in rat tissue. Mol Cell Endocrinol 1984;35:159-66.
66. Russell DH, Kibler R, Matrisian L, et al. Prolactin receptors on human T- and B-lymphocytes: antagonism of prolactin-binding by cyclosporin. J Immunol 1985;134: 3027-3031.
67. Carrier M, Wild J, Pelletier C, et al. Bromocriptine as an adjuvant to cyclosporine immunosuppression after heart transplantation. Ann Thorac Surg 1990;49:129-32.
68. Noel GL, Suh HK, Stone SJG, et al. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab 1972;35:840-51.
69. Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the euthyroid sick syndrome in critical illness. Clin Endocrinol 1994;41:731-7.
70. Meakins JL, Pietsch JB, Bubenick O, et al. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 1977; 188:241-50.
71. Devins SS, Miller A, Herndon BL, et al. Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients. Crit Care Med 1992;263:9682-5.
72. Belchetz PE, Plant TM, Nakai Y, et al. Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978; 202:631-3.
73. Santoro N, Filicori M, Crowley WF Jr. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin releasing hormone. Endocr Rev 1986; 7:11-23.
74. Klibanski A, Beitens IZ, Badger TM, et al. Reproductive function during fasting in man. J Clin Endocrinol Metab 1981;53:258-66.
75. Veldhuis JD, Iranmanesh A, Evans WS, et al. Amplitude suppression of the pulsatile mode of immunoradiometric LH release in fasting-induced hypoandrogenemia in normal men. J Clin Endocrinol Metab 1993;76:587-93.
76. Wang C, Chan V, Yeung RTT. Effect of surgical stress on pituitary-testicular function. Clin Endocrinol 1978;9:255-66.
77. Wang C, Chan V, Tse TF, et al. Effect of acute myocardial infarction on pituitary testicular function. Clin Endocrinol 1978;9:249-53.
78. Vogel AV, Peake GT, Rada RT. Pituitary-testicular axis dysfunction in burned men. J Clin Endocrinol Metab 1985;60:658-65.
79. Lephart ED, Baxter CR, Parker Jr CR. Effect of burn trauma on adrenal and testicular steroid hormone production. J Clin Endocrinol Metab 1987;64:842-8.
80. Kreutz LD, Rose RM, Jennings JR. Suppression of plasma testosterone levels and psychological stress: a longitudinal study of young men in officer candidate school. Arch Gen Psychiat 1972;26:479-82.
81. Aakvaag A, Bentdal O, Quigstad K, et al. Testosterone and testosterone binding globulin in young men during prolonged stress. Int J Androl 1978;1:22-31.
82. Van den Berghe G, de Zegher F, Lauwers P, et al. Luteinizing hormone secretion and hypoandrogenemia in critically ill men: effect of dopamine. Clin Endocrinol 1994;41:563-9.
83. Dong Q, Hawker F, McWilliam D, et al. Circulating immunoreactive inhibin and testosterone levels in patients with critical illness. Clin Endocrinol 1992;36:399-404.
84. Rivier C, Vale W. In the rat, interleukin 1-a acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion. Endocrinology 1989;124:2105-9.
85. Guo H, Calkins JH, Sigel MM, et al. Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis. Endocrinology 1990;127:1234-9.
86. Woolf PD, Hamill RW, McDonald JV, et al. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab 1985;60:444-50.
87. Spratt DI, Cox P, Orav J, et al. Reproductive axis suppression in acute illness is related to disease severity. J Clin Endocrinol Metab 1993;76:1548-54.
88. Cicero TJ, Bell RD, Wiest WG, et al. Function of the male sex organs in heroin and methadone users. N Engl J Med 1975;292:882-7.
89. Tweedle D, Walton C, Johnston IDA. The effect of an anabolic steroid on postoperative nitrogen balance. Br J Clin Pract 1972;27:130-2.
90. Van den Berghe G, Weekers F, Baxter RC, et al. Five days pulsatile GnRH administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. J Clin Endocrinol Metab 2001;86:3217-26.
91. O'Leary E, Hubbard K, Tormey W, et al. Laparoscopic cholecystectomy: hemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position. Br J Anaesth 1996;76:640-4.
92. Munck A, Guyre P, Holbrook N. Physiological functions of glucocorticoids during stress and their relation to pharmacological actions. Endocr Rev 1984;5:25-44.
93. Starling EH. The wisdom of the body. The Harveian Oration Delivered to the Royal College of Physicians. London: H.K. Lewis; 1923.
94. Cannon WB. The wisdom of the body. New York: Norton; 1932.
95. Vermes I, Bieshuizen A, Hampsink RM, et al. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995;80:1238-42.
96. Suzuki T, Suzuki N, Daynes RA, et al. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T-cells. Clin Immunol Immunopathol 1991; 61:202-11.
97. Parker LN, Levin ER, Lifrak E. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985;60:947-52.
98. Van den Berghe G, de Zegher F, Schetz M, et al. Dehydroepiandrosterone sulphate in critical illness: effect of dopamine. Clin Endocrinol 1995;43:457-63.
99. Zipser RD, Davenport MW, Martin KL, et al. Hyperreninemic hypoaldosteronism in the critically ill: a new entity. J Clin Endocrinol Metab 1981;53:867-73.
100. Barquist E, Kirton O. Adrenal insufficiency in the surgical intensive care unit patient. J Trauma 1997;42:27-31.
101. Annane D, Sebille V, Troche G, Raphael J-C, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45.
102. Beishuizen A, Vermes I, Hylkema BS, Haanen C. Relative eosinophilia and functional adrenal insufficiency in critically ill patients [letter]. Lancet 1999;353:1675-6.
103. Richards ML, Caplan RH, Wickus GG, Lambert PJ, Kisken WA. The rapid low-dose (1 microgram) cosyntropin test in the immediate postoperative period: results in elderly subjects after major abdominal surgery. Surgery 1999;125:431-40.
104. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supra-physiological doses of hydrocortisone. Crit Care Med 1998;26:645-50.
105. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-73.
106. Streeten DHP. What test for hypothalamic-pituitary adrenocortical insufficiency? Lancet 1999;354:179-80.
107. Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur J Endocrinol 2000;143:1-13.
108. Yeoh SI, Baxter RC. Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma. Acta Endocrinol (Copenh) 1988;119: 465-73.
109. Lewitt MS, Baxter RC. Regulation of growth hormone-indcpendent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants. J Clin Endocrinol Metab 1989;69:246-52.
110. Lewitt MS, Baxter RC. Inhibitors of glucose uptake stimulate the production of insulin-like growth factor binding protein (IGFBP-1) by human fetal liver. Endocrinology 1990;126:1527-33.
111. Baxter RC. Circulating binding proteins for the insulin-like growth factors. Trends Endocrin Met 1993;4:91-6.
112. Norrelund H, Fisker S, Vahl N, et al. Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels, experimental studies in normal, obese and GH-deficient adults. Growth Horm IGF Res 1999;9:52-60.
113. Olivecrona H, Hilding A, Ekström C, et al. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endocrinol Metab 1999; 84:553-60.
114. Delhanty PJD, Baxter RC. The regulation of acid-labile subunit gene expression and secretion by cyclic adenosine 3′,5′-monophosphate. Endocrinology 1998;139:260-5.
115. Hu M, Robertson DG, Murphy LJ. Growth hormone modulates insulin regulation of hepatic insulin-like growth factor binding protein-1 transcription. Endocrinology 1996; 137:3702-9.
116. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1357-67.